Parameter | Total population | CM | EM | |||
---|---|---|---|---|---|---|
Placebo | GMB 120 mg | Placebo | GMB 120 mg | Placebo | GMB 120 mg | |
MSQ total score | n = 84 | n = 94 | n = 41 | n = 40 | n = 43 | n = 54 |
Change from baseline, mean (SE) | 11.6 (2.6) | 26.0 (2.5) | 5.7 (3.1) | 24.4 (3.4) | 13.6 (3.4) | 22.1 (3.2) |
Difference, mean (SE) | 14.4 (2.8) | 18.7 (3.9) | 8.5 (3.8) | |||
P | <.0001 | <.0001 | 0.0267 | |||
MSQ role function restrictive | n = 84 | n = 94 | n = 41 | n = 40 | n = 43 | n = 54 |
Change from baseline, mean (SE) | 12.0 (2.8) | 27.3 (2.7) | 4.7 (3.4) | 25.2 (3.6) | 14.5 (3.6) | 22.7 (3.4) |
Difference, mean (SE) | 15.3 (3.0) | 20.5 (4.2) | 8.2 (4.0) | |||
P | <.0001 | <.0001 | 0.0426 | |||
MSQ role function emotional | n = 84 | n = 94 | n = 41 | n = 40 | n = 43 | n = 54 |
Change from baseline, mean (SE) | 14.5 (3.2) | 28.9 (3.1) | 9.2 (4.0) | 28.3 (4.4) | 14.7 (4.1) | 24.2 (4.0) |
Difference, mean (SE) | 14.4 (3.4) | 19.0 (5.0) | 9.5 (4.7) | |||
P | <.0001 | 0.0003 | 0.0479 | |||
MSQ role function preventive | n = 84 | n = 94 | n = 41 | n = 40 | n = 43 | n = 54 |
Change from baseline, mean (SE) | 8.8 (2.5) | 21.4 (2.4) | 3.5 (3.1) | 18.7 (3.3) | 10.9 (3.2) | 19.2 (3.0) |
Difference, mean (SE) | 12.6 (2.6) | 15.2 (3.8) | 8.3 (3.6) | |||
P | <.0001 | .0001 | .0233 | |||
Migraine Disability Assessment total score | n = 85 | n = 95 | n = 42 | n = 40 | n = 43 | n = 55 |
Change from baseline, mean (SE) | −2.5 (6.6) | −28.2 (6.5) | 8.9 (10.5) | −31.0 (11.8) | −8.0 (5.4) | −18.2 (5.2) |
Difference | ||||||
P | .0001 | .0026 | .084 | |||
Number of monthly migraine headache days with acute medication use | n = 86 | n = 98 | n = 42 | n = 42 | n = 44 | n = 56 |
Change from baseline, mean (SE) | −0.7 (0.7) | −5.3 (0.7) | −0.8 (1.0) | −7.0 (1.1) | −0.7 (0.8) | −3.5 (0.7) |
Difference, mean (SE) | −4.6 (0.7) | −6.2 (1.8) | −2.8 (0.8) | |||
P | <.0001 | <.0001 | .0008 |